Abstract:Key PointsEpigenetic regulation of gene expression relies on covalent, reversible and sequence-specific modifications of histone proteins that package DNA. Deregulation of this control mechanism can lead to multiple diseases.Acetylation and methylation of lysine and arginine residues are the most abundant modifications of the known histone marks. Histone acetyl marks are written by histone acetyltranferases, read by bromodomain-containing proteins and erased by histone deacetylases.Histone methyl marks are written by protein methyltransferases and read by proteins containing chromodomains, Tudor domains, malignant brain tumour domains, PWWP domains and plant homeodomain (PHD) fingers. Histone methyl marks are erased by lysine demethylases.Domains that write, read or erase histone marks are often grouped within a single gene, and these proteins are often combined within multiprotein complexes that mediate crosstalk between specific marks.When they are mutated, aberrantly expressed or driven by aberrant upstream signals, writers, readers and erasers of histone marks can affect the expression patterns of genes that lead to — or even drive — and maintain disease states. Direct associations have been observed in cancer, neuropsychiatric disorders, inflammation and metabolic diseases.Several histone deacetylase inhibitors have reached the clinic and two are approved in oncology. Small-molecule antagonists of bromodomain-containing proteins have demonstrated efficacy in animal models of cancer and inflammation. The chemical tractability of histone acetyltransferases, however, remains unclear.Potent protein methyltransferase inhibitors have been reported, and one compound was active against tumour xenografts in mice. Lysine demethylase inhibitors and antagonists of methyl-lysine readers are at an earlier development stage.

Epigenetic targets and drug discovery: part 1: histone methylation.

Epigenetic Targets and Drug Discovery Part 2: Histone Demethylation and DNA Methylation.

Epigenetic protein families: a new frontier for drug discovery

Epigenetics-targeted drugs: current paradigms and future challenges

Targeting epigenetic regulators for cancer therapy: modulation of bromodomain proteins, methyltransferases, demethylases, and microRNAs

Technologies of Targeting Histone Deacetylase in Drug Discovery: Current Progress and Emerging Prospects.

Chemical inhibitors targeting histone methylation readers

Targeting cancer epigenetic pathways with small-molecule compounds: Therapeutic efficacy and combination therapies

Epigenetic therapies targeting histone lysine methylation: complex mechanisms and clinical challenges

Acetylation- and Methylation-Related Epigenetic Proteins in the Context of Their Targets

Discovery of cysteine-targeting covalent histone methyltransferase inhibitors

Targeting Epigenetic Regulatory Enzymes for Cancer Therapeutics: Novel Small-Molecule Epidrug Development

Recent Advances in Targeting Histone H3 Lysine 36 Methyltransferases for Cancer Therapy

The Development of Epigenetics and Related Inhibitors for Targeted Drug Design in Cancer Therapy

Targeting Epigenetic Regulators with Covalent Small-Molecule Inhibitors

Peptide-based inhibitors of epigenetic proteins

Epigenetic Regulation and Drug Discovery for Cancer Therapy.

Drug discovery of histone lysine demethylases (KDMs) inhibitors (progress from 2018 to present)

Histone lysine methyltransferases as anti-cancer targets for drug discovery

Small molecules targeting selected histone methyltransferases (HMTs) for cancer treatment: Current progress and novel strategies

Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials